# LIGHT/TNFSF14 in allergic esophagitis remodeling

> **NIH NIH R01** · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2021 · $568,901

## Abstract

ABSTRACT
Chronic inflammation of the gastrointestinal mucosa can lead to fibrosis and other features of tissue
remodeling that limit normal functioning of the gastrointestinal tract. This is particularly apparent in patients with
Eosinophilic Esophagitis (EoE), an oral- and aero-antigen mediated allergic disease of increasing prevalence
and incidence. EoE is characterized by esophageal fibrosis and rigidity, and smooth muscle dysmotility,
resulting in food impactions and strictures, vomiting, poor appetite, failure to thrive, and dysphagia. Current
EoE treatments include antigen elimination diets and topical corticosteroids that can limit inflammation, but
these measures may not control disease long term or reverse the course of esophageal remodeling and
dysfunction. Although several inflammatory mediators are thought to contribute to inflammation in the
esophagus, specifically IL-5, IL-13, and TGFb, it is of great importance to extend our understanding of proteins
that drive fibrosis and remodeling in EoE, in order to define new potential targets for therapeutic intervention.
We have previously found that members of the tumor necrosis factor (TNF) superfamily, namely LIGHT
(TNFSF14) interacting with its two receptors HVEM (TNFRSF14) and LTbR (TNFRSF3), promote tissue
remodeling in the lungs and skin driven by allergens in models of severe asthma and atopic dermatitis. Based
on novel preliminary data that LIGHT, HVEM, and LTbR are over-expressed in esophageal tissue from active
EoE patients; that HVEM and LTbR are expressed in esophageal epithelial cells and fibroblasts and their
expression correlates with inflammatory mediators characteristic of EoE; that recombinant LIGHT is sufficient
to induce EoE-like remodeling features in the mouse esophagus; and that LIGHT-deficient mice are protected
from EoE-like disease induced by allergen, we propose to test the central hypothesis that LIGHT and its
receptors are pivotal mediators and drivers of allergic esophagus fibrosis and remodeling. In this multi-PI
application, we combine the expertise of Michael Croft (LJI and UCSD) who discovered the tissue remodeling
activities of LIGHT and Seema Aceves (UCSD) who demonstrated the presence and potential mechanisms of
esophageal remodeling in pediatric EoE subjects, with our co-investigator Richard Kurten (ACRI), an expert in
human ex vivo model systems in allergic diseases. We will utilize primary human esophageal EoE and normal
cells, tissues, and biopsies, as well as murine models of allergic esophagitis, in order to dissect the roles of
LIGHT in EoE pathogenesis. These studies will help unravel the mechanisms of esophageal tissue remodeling,
and have the potential for rapid clinical translation since LIGHT blocking antibodies are available for
therapeutic use.

## Key facts

- **NIH application ID:** 10115702
- **Project number:** 5R01DK114457-04
- **Recipient organization:** LA JOLLA INSTITUTE FOR IMMUNOLOGY
- **Principal Investigator:** Seema S Aceves
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $568,901
- **Award type:** 5
- **Project period:** 2018-04-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10115702

## Citation

> US National Institutes of Health, RePORTER application 10115702, LIGHT/TNFSF14 in allergic esophagitis remodeling (5R01DK114457-04). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10115702. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*